|
Okuno S.
Curr Opin Oncol. 2006 Jul;18(4):360-2.
Mammalian target of rapamycin inhibitors in sarcomas.
Medical Oncology, Mayo Clinic College of Medicine, Rochester,
Minnesota 55905, USA. okuno.scott@mayo.edu
PURPOSE OF REVIEW: Sarcomas are a rare malignancy accounting for less than 1% of
all cancers diagnosed annually. Standard chemotherapy has a response rate of
around 25% and newer agents are needed to improve the outcome in patients with
advanced sarcomas. The mammalian target of rapamycin plays a central role in
cell growth, proliferation, and apoptosis and its inhibition has demonstrated
antitumor activity in many tumors and shows promise against sarcomas. RECENT
FINDINGS: Recent studies of mammalian target of rapamycin inhibitors in sarcomas
have demonstrated clinical benefit response in sarcomas. SUMMARY: Clinical
benefit response uses standard Response Evaluation Criteria in Solid Tumors of
complete response and partial response as well as stable disease lasting at
least 4 months as an endpoint. This endpoint has been shown to select promising
new agents against sarcomas. Using this endpoint, the use of the mammalian
target of rapamycin inhibitor AP23573 has demonstrated activity against
sarcomas. The use of the inhibitor RAD001 (everolimus) along with imatinib in
patients with imatinib resistant gastrointestinal stromal tumor has shown
promise. Future studies will need to be performed to determine the clinical
differences among the mammalian target of rapamycin inhibitors in different
subsets of sarcomas.
PMID: 16721131
|
